N. Tekin Et Al. , "The alpha 2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits," PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR , vol.221, 2022
Tekin, N. Et Al. 2022. The alpha 2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR , vol.221 .
Tekin, N., Karamahmutoğlu, T., Aykaç, A., AKAKIN, D., & GÖREN, M. Z., (2022). The alpha 2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR , vol.221.
Tekin, Nurdan Et Al. "The alpha 2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits," PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR , vol.221, 2022
Tekin, Nurdan Et Al. "The alpha 2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits." PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR , vol.221, 2022
Tekin, N. Et Al. (2022) . "The alpha 2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits." PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR , vol.221.
@article{article, author={Nurdan Tekin Et Al. }, title={The alpha 2C-adrenoceptor antagonist JP-1302 controls behavioral parameters, tyrosine hydroxylase activity and receptor expression in a rat model of ketamine-induced schizophrenia-like deficits}, journal={PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR}, year=2022}